Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06198985
Other study ID # PamukkaleU-Karaköseli-002
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date January 1, 2024
Est. completion date July 1, 2025

Study information

Verified date December 2023
Source Pamukkale University
Contact Esra Karaköseli
Phone +905395765952
Email esra.karakoseli@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the study is to investigate the effect of dynamic balance exercises added to current medical treatment on balance in patients with ankylosing spondylitis.


Description:

The study was planned as a randomized controlled study. Forty participants with a clinically confirmed diagnosis of AS according to ASAS criteria will be recruited from the PAU Department of Physical Medicine and Rehabilitation (PMR). These participants who meet the inclusion and exclusion criteria will be randomly divided into 2 groups. The trial will be carried out at Pamukkale University Department of Physical Medicine and Rehabilitation between January 2024 and July 2025. The local ethics committee approved the study. All participants will be informed about the purpose and content of the study and will sign written consent to participate in the study. Participant's age, gender, body mass index, education, occupation, medications, duration of diagnosis, comorbidity, functional status and pain will be questioned and recorded. Group1: Group receiving dynamic balance exercise with tecnobody prokin 252 balance device added to current medical treatment (Intervention group) The first group will be given dynamic balance exercises with the tecnobody prokin 252 device and participants will continue their current medical treatment. These dynamic balance exercises will be performed in 3 days a week for 6 weeks. Each exercise will last 30 minutes. It will take 18 sessions in total. These exercises include 14 balance exercise movements performed on tecnobody prokin 252 balance device (manufactured in Italy). Group 2: Group receiving current medical treatment (control group) Participants in this group will receive only current medical treatment. Care will be taken not to change the medical treatments of the participants during the study. All participants will be evaluated with the following evaluation parameters before the treatment and at the end of 6 weeks.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 40
Est. completion date July 1, 2025
Est. primary completion date July 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Participants aged 18 to 65 years with a clinical diagnosis of ankylosing spondylitis according to ASAS criteria - To have the ability to give written informed consent - Having the ability to understand procedures Exclusion Criteria: - Visual and vestibular system diseases that may affect balance - Neurological or orthopedic diseases that may affect balance (Parkinson's disease, history of stroke, presence of knee or hip prosthesis, previous fracture sequelae, foot problems, etc.) - Individuals with severe mental and sensory problems - History of balance exercise and/or spine surgery in the last 6 months - Pregnancy or breastfeeding - Over 150 kg

Study Design


Intervention

Procedure:
Dynamic balance exercise with tecnobody prokin 252 balance device
Dynamic balance exercise with tecnobody prokin 252 balance device

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Hakan Alkan

Outcome

Type Measure Description Time frame Safety issue
Primary Dynamic balance measurements The TecnoBody Prokin 252 system was used to assess balance in the standing position for all participants. This equipment provides data on average track error and stability index. a day before rehabilitation
Primary Dynamic balance measurements The TecnoBody Prokin 252 system was used to assess balance in the standing position for all participants. This equipment provides data on average track error and stability index. 6 weeks after the start of rehabilitation
Secondary ASQoL A disease-specific, patient-completed outcome measure for patients with AS. The scale consists of 18 questions with two answers as 0 'no' and 1 'yes' for each item. The total score ranges from 0-18, with a high score indicating good quality of life. a day before rehabilitation
Secondary ASQoL A disease-specific, patient-completed outcome measure for patients with AS. The scale consists of 18 questions with two answers as 0 'no' and 1 'yes' for each item. The total score ranges from 0-18, with a high score indicating good quality of life. 6 weeks after the start of rehabilitation
Secondary Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) It consists of 6 VAS measures of fatigue, spinal and peripheral joint pain, tenderness and morning stiffness. Morning stiffness is measured in terms of both severity and duration. The mean score for the two questions on morning stiffness is calculated and summed with the scores for the other questions. The BASDAI score is obtained by converting the total value into a 0-10 scale. Below four is considered inactive disease and four and above is considered active disease. a day before rehabilitation
Secondary Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) It consists of 6 VAS measures of fatigue, spinal and peripheral joint pain, tenderness and morning stiffness. Morning stiffness is measured in terms of both severity and duration. The mean score for the two questions on morning stiffness is calculated and summed with the scores for the other questions. The BASDAI score is obtained by converting the total value into a 0-10 scale. Below four is considered inactive disease and four and above is considered active disease. 6 weeks after the start of rehabilitation
Secondary Bath Ankylosing Spondylitis Functional Index (BASFI) It is a quick, easy-to-administer functional index consisting of ten items developed to assess the functional status of patients. The total BASFI score is evaluated between 0-10. a day before rehabilitation
Secondary Bath Ankylosing Spondylitis Functional Index (BASFI) It is a quick, easy-to-administer functional index consisting of ten items developed to assess the functional status of patients. The total BASFI score is evaluated between 0-10. 6 weeks after the start of rehabilitation
Secondary Bath Ankylosing Spondylitis Metrology Index (BASMI) It is used to measure the level of spinal mobility of patients. The higher the BASMI score, the more severe the patient's limitation of movement. a day before rehabilitation
Secondary Bath Ankylosing Spondylitis Metrology Index (BASMI) It is used to measure the level of spinal mobility of patients. The higher the BASMI score, the more severe the patient's limitation of movement. 6 weeks after the start of rehabilitation
See also
  Status Clinical Trial Phase
Terminated NCT02685904 - A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis Phase 3
Completed NCT02186873 - A Study of Golimumab in Participants With Active Ankylosing Spondylitis Phase 3
Completed NCT01668004 - The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) Phase 4
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT01934933 - Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Phase 4
Not yet recruiting NCT04875299 - Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
Completed NCT02763111 - Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis Phase 2
Completed NCT02758782 - NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis Phase 4
Active, not recruiting NCT02687620 - Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT01750528 - Prevalence and Progression of Periodontitis in Ankylosing Spondylitis N/A
Completed NCT01463189 - Web-based Support to Manage Arthritis Pain Phase 2
Completed NCT01091675 - Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs Phase 3
Completed NCT00844805 - Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1) Phase 3
Recruiting NCT00747578 - Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan N/A
Completed NCT01083693 - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs N/A
Completed NCT00715091 - Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis Phase 4
Not yet recruiting NCT00517101 - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy N/A
Completed NCT00367211 - Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers. Phase 3
Completed NCT00133315 - TNFalfa Blocking Treatment of Spondylarthropathies Phase 4